XML 34 R23.htm IDEA: XBRL DOCUMENT v3.20.2
Collaboration and Other Agreements - Zai Lab (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Nov. 30, 2018
Sep. 30, 2020
Mar. 31, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Collaboration And Other Agreements [Line Items]              
Revenues   $ 18,253,000   $ 18,741,000 $ 52,192,000 $ 38,996,000  
Deferred revenue, current   9,259,000     9,259,000   $ 10,700,000
Zai Lab Agreement | Zai Labs              
Collaboration And Other Agreements [Line Items]              
Non-refundable upfront payment $ 25,000,000.0            
Non-refundable upfront payment, net of tax withholding 22,500,000            
Nonrefundable payment tax withholding $ 2,500,000            
Potential development and regulatory milestone payments under agreement   140,000,000.0     140,000,000.0    
Revenues     $ 4,000,000.0        
Revenues, Net Of Tax Withholding   0 3,600,000 4,000,000.0 3,600,000 12,100,000  
Revenues, Tax Withholding     $ 400,000        
Deferred revenue, current   5,000,000.0     5,000,000.0   $ 5,000,000.0
Zai Lab Clinical Supply Agreements | Zai Labs              
Collaboration And Other Agreements [Line Items]              
Revenues   $ 500,000   $ 0 $ 1,900,000 $ 0  
Zai Lab Agreement, Margetuximab | Zai Labs | Maximum              
Collaboration And Other Agreements [Line Items]              
Potential proceeds from royalties (percent) 20.00%            
Zai Lab Agreement, TRIDENT molecule | Zai Labs              
Collaboration And Other Agreements [Line Items]              
Potential proceeds from royalties (percent) 10.00%